As of Jan 17, 2025, Boston Scientific Corporation's Discounted Cash Flow (DCF) valuation estimates its share price at $21.3. This suggests it may be overvalued by (78.4%) compared to its current price of around $98.7, using a WACC of 7.7% and growth rates of 3.0%.
As of Jan 17, 2025, Boston Scientific Corporation's Weighted Average Cost of Capital (WACC) is approximately 7.7%.
As of Jan 17, 2025, Boston Scientific Corporation's Enterprise Value (EV) is approximately $40.0B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.